Charles River LaboratoriesCRL
CRL
$193.59
1.88%
Market Cap: $9.97B
0
Funds holding %
of 6,710 funds
0
Analysts bullish %
of 9 analysts
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
11% more repeat investments, than reductions
Existing positions increased: 258 | Existing positions reduced: 232
2% less funds holding
Funds holding: 666 [Q1] → 654 (-12) [Q2]
9.01% less ownership
Funds ownership: 110.81% [Q1] → 101.8% (-9.01%) [Q2]
14% less first-time investments, than exits
New positions opened: 76 | Existing positions closed: 88
15% less call options, than puts
Call options by funds: $54.2M | Put options by funds: $63.4M
23% less capital invested
Capital invested by funds: $14.2B [Q1] → $10.8B (-$3.32B) [Q2]
47% less funds holding in top 10
Funds holding in top 10: 15 [Q1] → 8 (-7) [Q2]
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$191
1%
downside
Avg. target
$221
14%
upside
High target
$250
29%
upside
9 analyst ratings
4 positive
44%
5 neutral
56%
0 negative
0%
TD Cowen Charles Rhyee 0 / 0 met price target | 5%upside $203 | Hold Maintained | 12 Aug 2024 |
Barclays Luke Sergott 71% 1-year accuracy 29 / 41 met price target | 8%upside $210 | Equal-Weight Maintained | 8 Aug 2024 |
UBS Dan Brennan 63% 1-year accuracy 15 / 24 met price target | 24%upside $240 | Buy Maintained | 8 Aug 2024 |
Evercore ISI Group Ross Muken 0 / 0 met price target | 16%upside $225 | Outperform Maintained | 8 Aug 2024 |
Goldman Sachs Matthew Sykes 66% 1-year accuracy 21 / 32 met price target | 29%upside $250 | Buy Maintained | 8 Aug 2024 |
Financial journalist opinion
Based on 7 articles about CRL published over the past 30 days